Highlights
- EPS (TTM)
- -$7.52
- Total Revenue (TTM)
- $112.00K
- Gross Profit (TTM)
- $21.00K
- EBITDA (TTM)
- -$14.90M
- Year Range
- $0.53 - $19.72
- ROA (TTM)
- -1,586.10%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in AIM ImmunoTech Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
AIM ImmunoTech Inc.
- 1D
- 6.17%
- 1M
- -35.54%
- YTD
- -46.57%
- 6M
- -77.97%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jun 17, 2025, AIM's average daily return is -1.01%, while the average monthly return is -21.42%.
Historically, 20% of months were positive and 80% were negative. The best month was Sep 2025 with a return of +11.8%, while the worst month was Jul 2025 at -66.2%. The longest winning streak lasted 1 consecutive months, and the longest losing streak was 3 months.
On a daily basis, AIM closed higher 42% of trading days. The best single day was Feb 13, 2026 with a return of +58.2%, while the worst single day was Jul 29, 2025 at -56.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.87% | -18.63% | -35.54% | -46.57% | |||||||||
| 2025 | -14.78% | -66.24% | -16.10% | 11.84% | -23.36% | -27.62% | -25.66% | -88.87% |
Benchmark Metrics
AIM ImmunoTech Inc. has an annualized alpha of -93.20%, beta of 1.00, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since June 18, 2025.
- This stock participated in 447.92% of S&P 500 Index downside but only -330.42% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -93.20%
- Beta
- 1.00
- R²
- 0.01
- Upside Capture
- -330.42%
- Downside Capture
- 447.92%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for AIM ImmunoTech Inc. (AIM) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the AIM ImmunoTech Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AIM ImmunoTech Inc. was 94.40%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current AIM ImmunoTech Inc. drawdown is 94.05%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -94.4% | Jun 18, 2025 | 196 | Mar 30, 2026 | — | — | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AIM ImmunoTech Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how AIM ImmunoTech Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AIM relative to other companies in the Biotechnology industry. Currently, AIM has a P/S ratio of 10.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |